Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Get the latest international news and world events from around the world.

Log in for authorized contributors

Nanoparticles from tattoos circulate inside the body, study finds

The elements that make up the ink in tattoos travel inside the body in micro and nanoparticle forms and reach the lymph nodes, according to a study published in Scientific Reports on 12 September by scientists from Germany and the ESRF, the European Synchrotron, Grenoble (France). It is the first time researchers have found analytical evidence of the transport of organic and inorganic pigments and toxic element impurities as well as in depth characterization of the pigments ex vivo in tattooed tissues. Two ESRF beamlines were crucial in this breakthrough.

“When someone wants to get a tattoo, they are often very careful in choosing a parlour where they use sterile needles that haven’t been used previously. No one checks the chemical composition of the colours, but our study shows that maybe they should,” explains Hiram Castillo, one of the authors of the study and scientist at the ESRF.

The reality is that little is known about the potential impurities in the colour mixture applied to the skin. Most tattoo inks contain organic pigments, but also include preservatives and contaminants like nickel, chromium, manganese or cobalt. Besides carbon black, the second most common ingredient used in tattoo inks is (TiO2), a white usually applied to create certain shades when mixed with colorants. TiO2 is also commonly used in food additives, sunscreens and paints. Delayed healing, along with skin elevation and itching, are often associated with white tattoos, and by consequence with the use of TiO2.

The AI tools shaping patient care may be operating outside regulatory oversight. MIT researchers say it’s time to change that

Every day, across thousands of American hospitals, artificial intelligence quietly shapes decisions that determine patient outcomes. An algorithm flags a patient as high risk for sepsis; a risk score informs whether a woman receives additional cancer screening; a deterioration model triggers an alert that sends a care team to a bedside. These tools are embedded in the workflows of nearly two-thirds of US hospitals, integrated into the electronic health record systems clinicians rely on daily. But many have never been reviewed by the FDA.

A new viewpoint in The Lancet Digital Health, co-authored by researchers at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and Jameel Clinic, traces how this problem took root, why it carries serious consequences, and what genuine transparency would require to fix it.

The argument, the scientists say, is not that AI has no place in clinical decision-making. It is that a $4 billion market of clinical decision support tools operates largely beyond public accountability, leaving patients and providers often unable to know whether the tools influencing their care have been validated, by whom, or for which populations they work as intended.

Long-read DNA test lifts rare disease diagnoses and could replace 15 other tests

A new test provides a much more complete picture of DNA than current standard diagnostics and leads to a diagnosis more often. The test can replace 15 other tests, making it faster and more efficient. Researchers from Radboud university medical center recommend in the New England Journal of Medicine that this test be adopted everywhere as the first choice for rare genetic disorders.

A condition is considered rare if it affects fewer than 1 in 2000 people. Nevertheless, up to 400 million people worldwide have a rare disease, as there are more than 7,000 different types. Eighty percent of these have a genetic cause. A diagnosis often takes years to obtain. Yet a diagnosis is important: It provides clarity, insight into the future, contact with others in similar situations, and the possibility to assess risks when planning to have children.

Researchers from Radboudumc and Maastricht UMC+ are working together to increase the chances of diagnosing genetic disorders. They compared current standard diagnostics—often involving multiple tests to reach a diagnosis—with a new DNA test in 1000 patients.

Scientists May Have Found a Protein That Spreads Aging

Ok so, the parabiosis was a temporary effect, but the answer turned out to be having a blood transfusion with yourself instead. So if this video is right there is a molecule called HMGB1 which can be blocked rather than having said transfusion.

Scientists may have identified one of the molecules that helps aging spread through the body.
Block HMGB1 in mice → less inflammation, better muscle regeneration, improved tissue repair.
The next wave of longevity therapies may focus on stopping aging signals, not just repairing the damage.

/* */